http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100772424-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-801 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2005-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100772424-B1 |
| titleOfInvention | Gene therapy for cancers comprising recombinant adeno-associated virus containing antisense cDNA of VEVV-A, VEVF-V, and VEVF-C and recombinant adeno-associated virus containing VEV truncated soluble DCNA |
| abstract | The present invention provides a gene therapy agent for cancer comprising a rAAV vector containing antisense cDNAs of VEGF-A, VEGF-B, and VEGF-C and a rAAV vector containing truncated soluble cDNA of VEGF receptor protein (VEGFR). It is about.n n n Gene therapeutic agents according to the present invention can be effectively used to treat cancer at the genetic level by inhibiting the expression and function of VEGF involved in angiogenesis essential for tumor growth and metastasis, thereby reducing tumor growth.n n n n rAAV, gene therapy, VEGF, VEGF receptor, adeno-associated virus |
| priorityDate | 2005-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.